The unprecedented growth of the high-throughput next-generation sequencing has facilitated the identification of rare oncogene fusions such as for NSCLC. rearrangement has been observed in only 2% of cases of NSCLC and has been successfully targeted using various tyrosine kinase inhibitors including crizotinib. However, the on-target and off-target mechanisms of the resistance are still vague. Here, we report a case of a patient with rearranged NSCLC presenting primary resistance to crizotinib.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8889240 | PMC |
| http://dx.doi.org/10.1016/j.jtocrr.2022.100286 | DOI Listing |
Publication Analysis
Top Keywords
unusual resistance
4
resistance mechanisms
4
mechanisms case
4
case -rearranged
4
nsclc
4
-rearranged nsclc
4
nsclc case
4
case report
4
report unprecedented
4
unprecedented growth
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!